|
1
|
Palumbo A and Anderson K: Multiple
myeloma. N Enq J Med. 364:1046–1060. 2011. View Article : Google Scholar
|
|
2
|
Rajkumar SV: Multiple myeloma: Every year
a new standard? Hematol Oncol. 37 (Suppl 1):S62–S65. 2019.
View Article : Google Scholar
|
|
3
|
Kumar SK, Rajkumar V, Kyle RA, van Duin M,
Sonneveld P, Mateos MV, Gay F and Anderson KC: Multiple myeloma.
Nat Rev Dis Primers. 3:170462017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Tandon N, Rajkumar SV, LaPlant B,
Pettinger A, Lacy MQ, Dispenzieri A, Buadi FK, Gertz MA, Hayman SR,
Leung N, et al: Clinical utility of the revised international
staging system in unselected patients with newly diagnosed and
relapsed multiple myeloma. Blood Cancer J. 7:e5282017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Martin T and Huff CA: Multiple myeloma:
Current advances and future directions. Clin Lymphoma Myeloma Leuk.
19:255–263. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kumar S, Paiva B, Anderson KC, Durie B,
Landgren O, Moreau P, Munshi N, Lonial S, Bladé J, Mateos MV, et
al: International myeloma working group consensus criteria for
response and minimal residual disease assessment in multiple
myeloma. Lancet Oncol. 17:e328–e346. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Paiva B, García-Sanz R and San Miguel JF:
Multiple myeloma minimal residual disease. Cancer Treat Res.
169:103–122. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Furukawa M, Ohkawara H, Ogawa K, Ikeda K,
Ueda K, Shichishima-Nakamura A, Ito E, Imai JI, Yanagisawa Y, Honma
R, et al: Autocrine and paracrine interactions between multiple
myeloma cells and bone marrow stromal cells by growth
arrest-specific gene 6 cross-talk with interleukin-6. J Biol Chem.
292:4280–4292. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Chong PSY, Zhou J, Lim JSL, Hee YT, Chooi
JY, Chung TH, Tan ZT, Zeng Q, Waller DD, Sebag M and Chng WJ: IL6
promotes a STAT3-PRL3 feedforward loop via SHP2 repression in
multiple myeloma. Cancer Res. 79:4679–4688. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Jurczyszyn A, Czepiel J, Biesiada G,
Gdula-Argasińska J, Cibor D, Owczarek D, Perucki W and Skotnicki
AB: HGF, sIL-6R and TGF-β1 play a significant role in the
progression of multiple myeloma. J Cancer. 5:518–524. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Altuvia Y, Landgraf P, Lithwick G, Elefant
N, Pfeffer S, Aravin A, Brownstein MJ, Tuschl T and Margalit H:
Clustering and conservation patterns of human microRNAs. Nucleic
Acids Res. 33:2697–2706. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wang R, Wang ZX, Yang JS, Pan X, De W and
Chen LB: MicroRNA-451 functions as a tumor suppressor in human
non-small cell lung cancer by targeting ras-related protein 14
(RAB14). Oncogene. 30:2644–2658. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Huang JY, Zhang K, Chen DQ, Chen J, Feng
B, Song H, Chen Y, Zhu Z, Lu L, De W, et al: MicroRNA-451:
Epithelial-mesenchymal transition inhibitor and prognostic
biomarker of hepatocelluar carcinoma. Oncotarget. 6:18613–18630.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kim Y, Powathil G, Kang H, Trucu D, Kim H,
Lawler S and Chaplain M: Strategies of eradicating glioma cells: A
multi-scale mathematical model with MiR-451-AMPK-mTOR control. PLoS
One. 10:e1143702015.
|
|
15
|
Yuan J, Lang J, Liu C, Zhou K, Chen L and
Liu Y: The expression and function of miRNA-451 in osteosarcoma.
Med Oncol. 32:3242015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Gits CM, van Kuijk PF, Jonkers MB, Boersma
AW, Smid M, van Ijcken WF, Coindre JM, Chibon F, Verhoef C,
Mathijssen RH, et al: MicroRNA expression profiles distinguish
liposarcoma subtypes and implicate miR-145 and miR-451 as tumor
suppressors. Int J Cancer. 135:348–361. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Liu X, Zhang A, Xiang J, Lv Y and Zhang X:
miR-451 acts as a suppressor of angiogenesis in hepatocellular
carcinoma by targeting the IL-6R-STAT3 pathway. Oncol Rep.
36:1385–1392. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Dimopoulos M, Terpos E, Comenzo RL, Tosi
P, Beksac M, Sezer O, Siegel D, Lokhorst H, Kumar S, Rajkumar SV,
et al: IMWG. International myeloma working group consensus
statement and guidelines regarding the current role of imaging
techniques in the diagnosis and monitoring of multiple myeloma.
Leukemia. 23:1545–1556. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Flores-Montero J, Sanoja-Flores L, Paiva
B, Puig N, García-Sánchez O, Böttcher S, van der Velden VHJ,
Pérez-Morán JJ, Vidriales MB, García-Sanz R, et al: Next generation
flow for highly sensitive and standardized detection of minimal
residual disease in multiple myeloma. Leukemia. 31:2094–2103. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Liu SY, Deng SY, He YB and Ni GX: MiR-451
inhibits cell growth, migration and angiogenesis in human
osteosarcoma via down-regulating IL 6R. Biochem Biophys Res Commun.
482:987–993. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Corre J, Cleynen A, Robiou du Pont S,
Buisson L, Bolli N, Attal M, Munshi N and Avet-Loiseau H: Multiple
myeloma clonal evolution in homogeneously treated patients.
Leukemia. 32:2636–2647. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Schwarzenbach H, Nishida N, Calin GA and
Pantel K: Clinical relevance of circulating cell-free microRNAs in
cancer. Nat Rev Clin Oncol. 11:145–156. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Filipów S and Łaczmański Ł: Blood
circulating miRNAs as cancer biomarkers for diagnosis and surgical
treatment response. Front Genet. 10:1692019. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Oura K, Fujita K, Morishita A, Iwama H,
Nakahara M, Tadokoro T, Sakamoto T, Nomura T, Yoneyama H, Mimura S,
et al: Serum microRNA-125a-5p as a potential biomarker of
HCV-associated hepatocellular carcinoma. Oncol Lett. 18:882–890.
2019.PubMed/NCBI
|
|
26
|
Hagrass HA, Sharaf S, Pasha HF, Tantawy
EA, Mohamed RH and Kassem R: Circulating microRNAs-a new horizon in
molecular diagnosis of breast cancer. Genes Cancer. 6:281–287.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Cui M, Wang H, Yao X, Zhang D, Xie Y, Cui
R and Zhang X: Circulating MicroRNAs in cancer: Potential and
challenge. Front Genet. 10:6262019. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Mollashahi B, Aghamaleki FS and Movafagh
A: The roles of miRNAs in medulloblastoma: A systematic review. J
Cancer Prev. 24:79–90. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Schwarzenbach H and Gahan PB: MicroRNA
shuttle from cell-to-cell by exosomes and its impact in cancer.
Noncoding RNA. 5:282019.
|
|
30
|
Zeng T, Peng L, Chao C, Fu B, Wang G, Wang
Y and Zhu X: miR-451 inhibits invasion and proliferation of bladder
cancer by regulating EMT. Int J Clin Exp Pathol. 7:7653–7662.
2014.PubMed/NCBI
|
|
31
|
Liu F, Bu Z, Zhao F and Xiao D: Increased
T-helper 17 cell differentiation mediated by exosome-mediated
microRNA-451 redistribution in gastric cancer infiltrated T cells.
Cancer Sci. 109:65–73. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Wang W, Zhang L, Wang Y, Ding Y, Chen T,
Wang Y, Wang H, Li Y, Duan K, Chen S, et al: Involvement of miR-451
in resistance to paclitaxel by regulating YWHAZ in breast cancer.
Cell Death Dis. 8:e30712017. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Rastgoo N, Abdi J, Hou J and Chang H: Role
of epigenetics-microRNA axis in drug resistance of multiple
myeloma. J Hematol Oncol. 10:1212017. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Ludwig N, Leidinger P, Becker K, Backes C,
Fehlmann T, Pallasch C, Rheinheimer S, Meder B, Stähler C, Meese E
and Keller A: Distribution of miRNA expression across human
tissues. Nucleic Acids Res. 44:3865–3877. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Panoutsopoulou K, Avgeris M and Scorilas
A: miRNA and long non-coding RNA: Molecular function and clinical
value in breast and ovarian cancers. Expert Rev Mol Diagn.
18:963–979. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Balakrishnan I, Yang X, Brown J,
Ramakrishnan A, Torok-Storb B, Kabos P, Hesselberth JR and Pillai
MM: Genome-wide analysis of miRNA-mRNA interactions in marrow
stromal cells. Stem Cells. 32:662–673. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Binder S, Zipfel I, Friedrich M, Riedel D,
Ende S, Kämpf C, Wiedemann K, Buschmann T, Puppel SH, Reiche K, et
al: Master and servant: LINC00152-a STAT3-induced long noncoding
RNA regulates STAT3 in a positive feedback in human multiple
myeloma. BMC Med Genomics. 13:222020. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
De Oliveira MB, Fook-Alves VL, Eugenio
AIP, Fernando RC, Sanson LFG, de Carvalho MF, Braga WMT, Davies FE
and Colleoni GWB: Anti-myeloma effects of ruxolitinib combined with
bortezomib and lenalidomide: A rationale for JAK/STAT pathway
inhibition in myeloma patients. Cancer Lett. 403:206–215. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Brown R, Yang S, Weatherburn C, Gibson J,
Ho PJ, Suen H, Hart D and Joshua D: Phospho-flow detection of
constitutive and cytokine-induced pSTAT3/5, pAKT and pERK
expression highlights novel prognostic biomarkers for patients with
multiple myeloma. Leukemia. 29:483–490. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Gocke CB, McMillan R, Wang Q, Begum A,
Penchev VR, Ali SA, Borrello I, Huff CA and Matsui W: IQGAP1
Scaffold-MAP kinase interactions enhance multiple myeloma
clonogenic growth and self-renewal. Mol Cancer Ther. 15:2733–2739.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Mimura N, Hideshima T, Shimomura T, Suzuki
R, Ohguchi H, Rizq O, Kikuchi S, Yoshida Y, Cottini F, Jakubikova
J, et al: Selective and potent Akt inhibition triggers anti-myeloma
activities and enhances fatal endoplasmic reticulum stress induced
by proteasome inhibition. Cancer Res. 74:4458–4469. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Berenstein R, Nogai A, Waechter M, Blau O,
Kuehnel A, Schmidt-Hieber M, Kunitz A, Pezzutto A, Dörken B and
Blau IW: Multiple myeloma cells modify VEGF/IL-6 levels and
osteogenic potential of bone marrow stromal cells via
Notch/miR-223. Mol Carcinog. 55:1927–1939. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Matthews GM, de Matos Simoes R, Dhimolea
E, Sheffer M, Gandolfi S, Dashevsky O, Sorrell JD and Mitsiades CS:
NF-κB dysregulation in multiple myeloma. Semin Cancer Biol.
39:68–76. 2016. View Article : Google Scholar : PubMed/NCBI
|
